Form 4: Alaunos Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Holger Weis, a director of Alaunos Therapeutics, acquired 10,904 employee stock options on April 13, 2025, at an exercise price of $2.92.
Summary
- On April 13, 2025, Holger Weis, a director of Alaunos Therapeutics, acquired 10,904 employee stock options.
- The exercise price for these options is $2.92.
- The options are fully vested as of April 13, 2025, and expire on April 12, 2035.
- Following the transaction, Weis directly owns 10,904 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. While insider confidence can be a positive signal, this is a routine transaction.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- Shareholders may view the acquisition of stock options by a director as a sign of confidence in the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 04/13/2025 | Date of earliest transaction: Holger Weis acquired employee stock options. |
| 04/13/2025 | Options are fully vested. |
| 04/12/2035 | Expiration date of the employee stock options. |
| 04/15/2025 | Date of signature on the Form 4 filing. |
Keywords
Alaunos Therapeutics, Director, Stock Options, Form 4, Beneficial Ownership, TCRT, Holger Weis
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.